Vaishali Pharma Limited VAISHALI NSEPHARMA
Company Overview
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, antimalarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutical products; and oncology products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.
Why Investors Should Care
Revenue has grown at a 11.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.27.
Recent Developments
- Mar 2025 Revenue of ₹97.88 Cr (+19.7% YoY); net profit ₹81.74 L.
- Trailing 12 Months Year-on-year growth — revenue -16.5%, earnings +13.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.0%, profit CAGR -41.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.02% |
| 1 Year: | -16.50% |
Compounded Profit Growth
| 5 Years: | -41.21% |
| 1 Year: | 13.70% |
Stock Price Performance
| 1 Year: | -38.78% |
| 6 Months: | -0.38% |
| 3 Months: | +6.43% |
| 1 Month: | +6.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.65 · Neutral
P/E of 132.33 is above the sector median of 35.94 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.0% over 5 years.
CONS
- Trading at a high P/E of 132.3.
- Earnings shrank at -41.2% CAGR over 5 years.
- Trading 38.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VAISHALI Vaishali Pharma Limited NSEPHARMA | 7.94 | 132.33 | ₹103.59 Cr | 0.00% | 4.72% | 6.21% | 11.02% | -41.21% |
| 2 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,974.50 | 66.71 | ₹1.29 L Cr | 0.22% | 19.79% | 21.50% | 15.33% | 33.34% |
| 3 | ALKEM Alkem Laboratories Limited NIFTY_MIDNSEPHARMA | 5,597.50 | 29.07 | ₹66,926.51 Cr | 0.35% | 18.56% | 17.56% | 8.30% | 32.74% |
| 4 | ABBOTINDIA Abbott India Limited NIFTY_MIDNSEPHARMA | 27,855.00 | 38.12 | ₹59,189.93 Cr | 1.89% | 41.87% | 34.46% | 9.01% | 17.80% |
| 5 | ANTHEM ANTHEM BIOSCIENCES LTD NIFTY_MIDNSEPHARMA | 825.65 | 81.26 | ₹46,377.90 Cr | 0.24% | 26.77% | 19.45% | 26.20% | 15.39% |
| 6 | AJANTPHARM Ajanta Pharma Limited NIFTY_MIDNSEPHARMA | 3,470.40 | 38.28 | ₹43,357.66 Cr | 1.86% | 29.41% | 23.33% | 13.40% | 21.55% |
| 7 | AGARWALEYE DR AGARWALS HEALTH CARE L NSEPHARMA | 532.30 | 127.96 | ₹16,875.30 Cr | 0.00% | 9.74% | 6.58% | 26.96% | 12.28% |
| 8 | APLLTD Alembic Pharmaceuticals Limited NSEPHARMA | 834.45 | 23.67 | ₹16,402.21 Cr | 1.49% | 12.77% | 12.36% | 9.46% | 25.42% |
| 9 | ALIVUS Alivus Life Sciences Limited NSEPHARMA | 1,325.20 | 27.06 | ₹16,265.43 Cr | 0.38% | 21.78% | 16.94% | 7.61% | 6.53% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 |
|---|---|---|
| Revenue | 27.91 Cr | 31.10 Cr |
| Cost of Revenue | 23.74 Cr | 30.64 Cr |
| Gross Profit | 4.18 Cr | 45.76 L |
| Operating Expenses | 2.93 Cr | 32.51 L |
| Operating Income | 1.24 Cr | 13.25 L |
| EBITDA | 2.43 Cr | -4.55 Cr |
| Interest Expense | 38.44 L | 92.60 L |
| Pretax Income | 1.93 Cr | -5.60 Cr |
| Tax Provision | 48.50 L | -1.31 Cr |
| Net Income | 1.44 Cr | -4.29 Cr |
| Diluted EPS | 0.98 | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 71.54 Cr | 63.82 Cr | 81.76 Cr | 97.88 Cr |
| Cost of Revenue | 63.50 Cr | 54.68 Cr | 74.42 Cr | 85.67 Cr |
| Gross Profit | 8.04 Cr | 9.15 Cr | 7.35 Cr | 12.21 Cr |
| Operating Expenses | 1.56 Cr | 17.50 L | 1.01 Cr | 6.31 Cr |
| Operating Income | 6.48 Cr | 8.97 Cr | 6.34 Cr | 5.90 Cr |
| EBITDA | 8.67 Cr | 11.61 Cr | 3.70 Cr | 3.78 Cr |
| Interest Expense | 2.49 Cr | 2.26 Cr | 2.27 Cr | 2.07 Cr |
| Pretax Income | 5.73 Cr | 8.85 Cr | 92.61 L | 1.23 Cr |
| Tax Provision | 1.70 Cr | 2.24 Cr | 20.72 L | 40.84 L |
| Net Income | 4.02 Cr | 6.60 Cr | 71.89 L | 81.74 L |
| Diluted EPS | 0.38 | 0.59 | 0.07 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 81.62 Cr | 78.90 Cr | 79.96 Cr | 109.84 Cr |
| Current Assets | 76.43 Cr | 72.67 Cr | 74.52 Cr | 104.48 Cr |
| Cash & Equivalents | 1.16 Cr | 52.91 L | 1.46 Cr | 1.71 Cr |
| Inventory | 62.90 L | 3.05 Cr | 37.97 L | 4.81 Cr |
| Receivables | 58.51 Cr | 53.61 Cr | 49.43 Cr | 46.72 Cr |
| Total Liabilities | 55.27 Cr | 38.37 Cr | 37.12 Cr | 44.93 Cr |
| Current Liabilities | 51.94 Cr | 32.07 Cr | 33.08 Cr | 40.05 Cr |
| Long Term Debt | 3.11 Cr | 5.23 Cr | 3.60 Cr | 4.20 Cr |
| Total Debt | 20.81 Cr | 14.74 Cr | 13.49 Cr | 12.32 Cr |
| Total Equity | 26.35 Cr | 40.53 Cr | 42.84 Cr | 64.92 Cr |
| Shares Outstanding | 10.55 Cr | 10.55 Cr | 10.72 Cr | 13.05 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 1.32 Cr | 1.08 Cr | 80.67 L | -18.04 Cr |
| Investing Cash Flow | -84.68 L | 28.21 L | 1.20 Cr | -18.81 L |
| Financing Cash Flow | 41.75 L | -1.73 Cr | -1.42 Cr | 18.49 Cr |
| Capital Expenditure | -86.48 L | -29.72 L | -11.10 L | -30.46 L |
| Free Cash Flow | 45.38 L | 78.24 L | 69.57 L | -18.34 Cr |
| Net Change in Cash | 88.93 L | -37.05 L | 59.36 L | 26.47 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 11.2% | 14.3% | 9.0% | 12.5% |
| Operating Margin % | 9.1% | 14.1% | 7.8% | 6.0% |
| Net Margin % | 5.6% | 10.3% | 0.9% | 0.8% |
| ROE % | 15.3% | 16.3% | 1.7% | 1.3% |
| ROCE % | 21.8% | 19.2% | 13.5% | 8.5% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VAISHALI
Vaishali Pharma adjusts allotment consideration based on valuation report - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNbjJpaFZpa3V2eXp4ZFoyMVRIOG53aldJdUJweGliSFF5Ymc5d1R6cHdEU0tSdmx1ZzU5ekI1aFFtMW5tU3JWME5idXN1OW91Y2pVYnUtcnVfZU9lcHFZM3lubS02bTZKdExaSlA2QzlibEN1MUVBVUNRQ0Jab0Vwb1prenpqRFAyakIyc3…
Vaishali Parekh’s Stock Picks: Latent View, Precision Camshafts, IEX on Radar for June 1, 2026 - New Analyst Coverage - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNQ0N4aWszSWZvZzF2bU9xMFZtS0FFSGtQU0UyN2dtQ0dJSUhFRV9UNFcwV19hc1ZVYjNxdXhJTlFENWRFNjRBOXU1X19VZTJQcEthS2lDNldFVXpjTlpPVE5wME0zdVR4UjNjTmVraHlpX1gyTjhVeWg3R2NRZXRiRWJXYm5JTkpQdEtYQW…
Buy, Sell Or Hold: Bharat Electronics, Tata Steel, HDFC Bank, Epack Durable, And More — Ask Profit - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOSFd6RXJUd3lCSkR0S2s1WVd4eGFTOTBQZmJ6UkxvLU5kVS1KOV9ZQ1dtQTlvWFhFbU5CWXplbmVNSUZxUHJ0TUhsYjhzR25SSXZ1MXN3T1ZYNGI1UDFXcEYwdklycWI2YWMxR0kxTXRMV2JiTEUtWlJPM3hxV3I0ZnBxOS1YRE1YQ3hKNV…
Vaishali Pharma allots 45.37 lakh shares at ₹20 each to Kesar Pharma - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPWVg5dUs4RU5hUzdJUEVsWGpQQy1aOXpQTmI2NEhjN3kyV0p2R1JtamdEQUFxdDl5VU04VVBMclFnQVEyZnhldFZqc1NhcFVNTEZUOXk3S0s1dDJrNlRKNEIybWpOSjZ4RVJMbjNjVXBBTFhBeklKY3daTVctek9USldIdjN1UUgtREY2SW…
Vaishali Parekh Identifies Three Potential Stock Opportunities for May 27, 2026 - Capex Guidance - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPUE1kY0JCQWdRSUsycVI3OHFfQ2puVXBWLVRNMFVBSjR0bkRuLXdKaEJ0ZDA1SkN2TWhkeFhRbFhlUlZKSlRXTlA4ajV0ZS1NaldKMU9oZ21nM3JrN3VmejdQZ2pGWVRrdlcxT2tMLTJTNlpDWHVlTmlCdFZWcnkwQUNHT05UaTBXd3pMLT…
Buy, Sell Or Hold: State Bank Of India, RVNL, NHPC, ITC, Britannia — Ask Profit - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQZ2NLRlR5c2xmd0FEUHNRVlZ0QXNQcnRMVUVhYnNBdHQtU2lzc2lLdlpVRFFERkJ1ZjREZUdocl9QSG5MR2pER016X2lBRVV1ZEdNYVJ3LXhsZVhEQV9jVTRtQ2F5TTFEa3FKRjkydFd1Zm85ZEk0NG91RkVZUThPZklTWFVQYVItOU1tT1…
VAISHALI — Frequently Asked Questions
What is the current share price of Vaishali Pharma Limited (VAISHALI)?
As of 2026-08-07 06:31 IST, Vaishali Pharma Limited (VAISHALI) trades at ₹7.94 on NSE. Its 52-week range is ₹4.88 to ₹12.97.
What is the market capitalisation of VAISHALI?
Vaishali Pharma Limited (VAISHALI) has a market capitalisation of ₹103.59 Cr on NSE.
What is the P/E ratio of VAISHALI?
VAISHALI trades at a trailing price-to-earnings (P/E) ratio of 132.33. The industry average P/E is 35.94. Its price-to-book (P/B) ratio is 1.51.
What is the return on equity (ROE) of VAISHALI?
VAISHALI has a return on equity (ROE) of 6.21%. Its return on capital employed (ROCE) is 4.72%.
Is VAISHALI a good stock to buy?
This page provides a data-driven analysis of Vaishali Pharma Limited (VAISHALI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.